Life Sciences

Meet the Co-chairs - TAGLAW

Tauber, Paul J.
Coblentz, Patch, Duffy & Bass LLP

Life Sciences Specialty Group Report

The TAGLaw Life Sciences Specialty Group is comprised of lawyers in TAGLaw firms around the world who have special expertise in one or more of the life sciences industries: pharmaceuticals, biotechnologicals, medical devices, nutritionals, and personal care.

TAGLaw member firms provide a variety of legal services relating to the research, product discovery, product development, manufacture, distribution, marketing and sale of products locally and across national borders. Our TAGLaw members have extensive legal and technical expertise in intellectual property law prosecution and litigation, as well as expertise relating to clinical development, licensing/ collaborations, government and regulatory matters, manufacturing, pricing, regulation of marketing and sale of products, and government affairs. The Group includes members with competition/antitrust expertise and firms with extensive finance and M&A experience to help life sciences companies fund operations and growth, and achieve corporate objectives. Members of the Group also offer related expertise in corporate organization/business structures, corporate compliance, dispute settlement, taxation, personnel/labor and related matters.

The Life Sciences Specialty Group has cooperated with the Intellectual Property and Information Technology Specialty Group for excellent programming at the last three TAGLaw international meetings. Those topics were:

• The TAGLaw Approach to Seeking Emergency Relief for IP Infringement Around the Globe
• Cross Border IP Deals: A case study of common provisions and pitfalls encountered when licensing complex, high-value intellectual property rights on an international basis
• Advising Licensors of Intellectual Property in Difficult Economic Times

TAGLaw firms that provide services to the life sciences industries are invited to submit firm profiles for the TAGLaw–Life Sciences webpage and to add individual lawyers to the member list.

Life Sciences  Mini-Conference - January 19&20, 2007

In January, the Life Sciences Specialty Group did something no other specialty group has yet done in TAGLaw - and the results were momentous.

The group met outside of a TAGLaw semi-annual conference to put full focus on the possibilities of collaboration. The conference worked much like a regional meeting, but attendance and discussion was based on industry opportunity rather than geographic proximity. This also meant that the conference pulled together lawyers from a variety of practice areas, but all sharing their common experience in medical device, pharmaceutical, biotech, bioscience or nutritionals industries.

Members attending the meeting quickly discovered a potential for the collaboration of worldwide capabilities and the forming of a "Dream Team" – a nickname coined for the Life Sciences group and referenced frequently during the conference. A number of actions developed from this meeting that will lead to more collaboration.

1. Participants in the group would submit a capability statement outlining their background and the types of clients that have acted for
2. A special Life Sciences “micro-site” would be developed apart from the current TAGLaw website to market these capabilities to potential clients
3. Under the direction of the co-chairs, the groups will now consider joint visits to prospective clients, webinars, and coordinated attendances at relevant industry conventions.
Watch, in the coming months, for further developments within the Life Sciences group…perhaps your TAGLaw Specialty Group has similar potential!


[Note:  For a fully formatted version of this article, click on the link below.] 


INSIDER TRADING AND CLINICAL TRIALS By Donald F. Crane* We are asked regularly about guidelines as to when it is appropriate to buy or sell stock in a public company. One context in which this often comes up is during clinical trials conducted by life sciences companies. In view of recent attention by the Congress and the SEC (see New York Times August 9, 2005), we thought it would be useful to call your attention to this important subject. Insider Trading in Clinical Trials In general, a person may not buy or sell stock in the public markets when aware of material information that is not available to the public and has been gained through a confidential relationship. Illegal insider trading occurs by use of inside knowledge to gain a trading advantage – profiting or avoiding losses – to the detriment of the rest of the market that does not yet have access to this information. Starting with a few basic, but important, concepts:  Information is material if it would be considered important in the total mix of information a reasonable investor would consider in making an investment decision. 



Read more: Insider Trading and Clinical Trials